In order to reach an improved tumor localization and enable targeted radiotherapy of malignant insulinomas as well as of other GLP-1R-overexpressing malignancies, further investigations on pharmacokinetically optimized peptides should be envisaged. The gene discussed is GLP1R; the disease is pancreatic insulinoma.